Previous studies on the relationship between metformin therapy and prostate cancer risk have yielded conflicting results. Cancer researchers are not sure how to explain these findings. In recent years, new evidence suggested that the effect of metformin on prostate cancer risk might vary in different ethnicities. As we enter the era of precision medicine, to clarify the effect of metformin on cancer risk, race-specific molecular factors should be considered and incorporated into future prostate cancer studies.
- Received July 1, 2016.
- Accepted July 6, 2016.
- Copyright ©2016, American Association for Cancer Research.